78089-99-3

Basic information

• Product Name: (2E)-3-(DiMethylaMino)-1-(4-nitrophenyl)prop-2-en-1-one
• Synonyms: (2E)-3-(DiMethylaMino)-1-(4-nitrophenyl)prop-2-en-1-one;2-Propen-1-one, 3-(dimethylamino)-1-(4-nitrophenyl)-, (2E)-
• CAS NO: 78089-99-3
• Molecular Formula: C₁₁H₁₂N₂O₃
• Molecular Weight: 220.22458
• Mol File: 78089-99-3.mol
• Article Data: 26

Chemical Properties

• Melting Point: 139-141 °C(Solv: hexane (110-54-3))
• Boiling Point: 357.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.202±0.06 g/cm3(Predicted)
• PKA: 4.72±0.70(Predicted)
• CAS DataBase Reference: (2E)-3-(DiMethylaMino)-1-(4-nitrophenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-3-(DiMethylaMino)-1-(4-nitrophenyl)prop-2-en-1-one(78089-99-3)
• EPA Substance Registry System: (2E)-3-(DiMethylaMino)-1-(4-nitrophenyl)prop-2-en-1-one(78089-99-3)

Safety Data

• Hazardous Substances Data: 78089-99-3(Hazardous Substances Data)

Usage

General Description

The chemical compound (2E)-3-(Dimethylamino)-1-(4-nitrophenyl)prop-2-en-1-one is a substituted enone with a nitrophenyl group. It is a yellow crystalline compound that is commonly used as a reactant in organic synthesis and as a starting material for the preparation of various pharmaceuticals and agrochemicals. The presence of the dimethylamino group and the nitrophenyl group makes it a versatile compound for the synthesis of a wide range of organic molecules. It is also known for its strong electron-withdrawing properties, making it useful in various chemical reactions and transformations. Overall, this compound has significant applications in the field of organic chemistry due to its unique chemical structure and reactivity.

Upstream product

• 37062-23-0 3-Hydroxy-1-(4-nitro-phenyl)-prop-2-en-1-on 
• 124-40-3 dimethyl amine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 100-19-6 (4-nitrophenyl)ethanone 
• 68-12-2 N,N-dimethyl-formamide 
• 98-86-2 acetophenone 
• 4909-78-8 N,N-dimethylformamide dineopentyl acetal 
• 20353-93-9 <3-(dimethylamino)-2-azaprop-2-en-1-ylidene> dimethylammonium chloride 

Downstream Products

• 100970-07-8 ethyl 2-methyl-6-(4-nitrophenyl)pyridine-3-carboxylate 
• 1348399-58-5 4-[4-(4-Nitro-phenyl)-pyrimidin-2-ylamino]-benzenesulfonamide 
• 1010796-77-6 4-dimethylamino-3-(4-nitrobenzoyl)-2-oxobut-3-enoic acid ethyl ester 
• 1010796-78-7 2-dimethylaminomethylene-4,4,4-trifluoro-1-(4-nitrophenyl)butane-1,3-dione 
• 73387-59-4 1-methyl-3-(4-nitrophenyl)-1H-pyrazole 
• 916766-82-0 4-(1-methyl-1H-pyrazol-3-yl)aniline 
• 1246093-53-7 4-(benzo[4,5]imidazo[1,2-a]pyrimidin-2-yl)aniline 
• 1246093-55-9 4-(benzo[4,5]imidazo[1,2-a]pyrimidin-2-yl)-N-(3-fluoropropyl)aniline 
• 1246093-54-8 2-(4-nitrophenyl)benzo[4,5]imidazo[1,2-a]pyrimidine 
• 945354-76-7 4-(4-nitrophenyl)benzo[4,5]imidazo[1,2-a]pyrimidine 
• 931114-27-1 [7-(4-amino-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-thiophen-2-yl-methanone 

Relevant articles and documents

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

By removing 5-methyl and 6-acetyl groups in our previously reported compound 3, we designed a series of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential tubulin polymerization inhibitors. Among them, compound 5e displayed low nanomolar antiproliferative efficacy on HeLa cells which was 166-fold higher than the lead analogue 3. Interestingly, 5e displayed significant selectivity in inhibiting cancer cells over HEK-293 (normal human embryonic kidney cells). In addition, 5e dose-dependently arrested HeLa in G2/M phase through the alterations of the expression levels of p-cdc2 and cyclin B1, and caused HeLa cells apoptosis by regulation of expressions of cleaved PARP. Further evidence demonstrated that 5e effectively inhibited tubulin polymerization and was 3-fold more powerful than positive control CA-4. Moreover, molecular docking analysis indicated that 5e overlapped well with CA-4 in the colchicine-binding site. These studies demonstrated that 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine skeleton might be used as the leading unit to develop novel tubulin polymerization inhibitors as potential anticancer agents.

Novel 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salts thereof

The present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a novel 4-carbonylamino-4-phenylpyrimidine compound or a pharmaceutically ac

Design, synthesis, and biological evaluation of triazolyl- and triazinyl-quinazolinediones as potential antitumor agents

Novel 6(3-1H-1,2,4-triazol-1-yl)-3-phenylquinazoline-2,4(1H,3H)-diones (7a-e) were synthesized from different enaminones (6a-e) with 6-hydrazinyl-3-phenylquinazoline-2,4(1H,3H)-dione. 2,6(4-2-Substituted-1,3,5-triazin-1(2H)-yl)-3-phenylquinazoline-2,4(1H,3H)-diones (8a-k) were synthesized from the reaction of 1-(2,4-dioxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-6-yl)thiourea, urea, or guanidine (3a-c) with enaminones (6a-e), and a series from 3-substituted-2-imino-1,3,5-triazin-1(2H)-yl-sulfonyl-phenyl-1-methylquinazoline-2,4(1H,3H)-dione (12a-j) were obtained from the reaction of N-(diaminomethylene)-4-(1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)benzenesulfonamide (11) with the enaminone (6a-j). The antitumor activity of the synthesized compounds was evaluated against two human cell lines: human colon carcinoma HCT116 and human hepatocellular carcinoma HEP-G2. Some of the tested compounds showed significant potency compared to the reference drug staurosporin.